This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agilon (AGL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
T, AGL and ALTO have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2023.
New Strong Sell Stocks for March 15th
by Zacks Equity Research
AGL, BFIN and SNBR have been added to the Zacks Rank #5 (Strong Sell) List on March 15, 2024.
New Strong Sell Stocks for February 28th
by Zacks Equity Research
AGL, BELFB and DRVN have been added to the Zacks Rank #5 (Strong Sell) List on February 28, 2023.
Agilon (AGL) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Agilon (AGL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -46.43% and 0.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Agilon (AGL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Agilon (AGL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Analysts Estimate Agilon Health (AGL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agilon (AGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is VanEck Morningstar International Moat ETF (MOTI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOTI
Compared to Estimates, Agilon (AGL) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Agilon (AGL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilon Health (AGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -300% and 3.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sotera Health Company (SHC): Can Its 17.3% Jump Turn into More Strength?
by Zacks Equity Research
Sotera Health Company (SHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Agilon Health (AGL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of 33.33% and 5.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates
by Kaibalya Pravo Dey
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
Implied Volatility Surging for agilon health (AGL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to agilon health (AGL) stock based on the movements in the options market lately.
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -75% and 3.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health (AGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -40% and 6.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?